US 11,718,681 B2
Anti-SIRP α antibodies
Gijsbertus Franciscus Maria Verheijden, Nijmegen (NL); Gerard Rouwendal, Nijmegen (NL); Roland Jan Arends, Nijmegen (NL); Timo Kars Van Den Berg, Amsterdam (NL); Hanke Lottie Matlung, Amsterdam (NL); and Katarina Franke, Amsterdam (NL)
Assigned to Byondis B.V., Nijmegen (NL)
Filed by Byondis B.V., Nijmegen (NL)
Filed on Feb. 2, 2022, as Appl. No. 17/591,231.
Application 17/591,231 is a division of application No. 16/614,199, granted, now 11,274,159, previously published as PCT/EP2018/062473, filed on May 15, 2018.
Claims priority of application No. 17171285 (EP), filed on May 16, 2017.
Prior Publication US 2022/0195063 A1, Jun. 23, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01)] 23 Claims
 
1. A method for treating human solid tumours or haematological malignancies, which comprises administering an anti-SIRPα antibody, or an antigen-binding fragment thereof, to a patient in need thereof, wherein the anti-SIRPα antibody or the antigen-binding fragment thereof comprises heavy chain (HC) and light chain (LC) variable region (VR) complementarity determining regions (CDRs) selected from the group consisting of:
(a) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:3 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:4;
(b) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:5 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:6;
(c) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:7 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:8;
(d) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:9 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:10;
(e) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:11 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:12;
(f) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:13 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:14;
(g) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:15 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:16; and
(h) CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO: 17 and CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO: 18; and
wherein the CDRs are determined according to Kabat numbering; and
wherein said human solid tumour or haematological malignancy expresses SIRPα.